AVA-101: Phase IIb discontinued

Avalanche said it will not begin a Phase IIb trial of AVA-101 this half to treat wet AMD after further analyses of data from a Phase IIa trial of the compound in the indication. Instead, the company is conducting preclinical studies to investigate the optimal dose and delivery of AVA-101 and AVA-201 vs. standard-of-care anti-VEGF protein therapy to select a new clinical candidate. AVA-201 delivers the same gene as AVA-101 via a next-generation vector. ...